California Public Employees Retirement System lowered its position in Radius Health, Inc. (NASDAQ:RDUS) by 4.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 70,000 shares of the biopharmaceutical company’s stock after selling 3,100 shares during the period. California Public Employees Retirement System owned approximately 0.16% of Radius Health worth $2,706,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in the company. Russell Investments Group Ltd. acquired a new stake in Radius Health during the fourth quarter worth about $197,000. Guggenheim Capital LLC raised its stake in Radius Health by 3.9% in the fourth quarter. Guggenheim Capital LLC now owns 65,355 shares of the biopharmaceutical company’s stock worth $2,485,000 after buying an additional 2,453 shares during the last quarter. Norges Bank acquired a new stake in Radius Health during the fourth quarter worth about $13,519,000. Teachers Advisors LLC raised its stake in Radius Health by 3.4% in the fourth quarter. Teachers Advisors LLC now owns 51,735 shares of the biopharmaceutical company’s stock worth $1,967,000 after buying an additional 1,692 shares during the last quarter. Finally, Highbridge Capital Management LLC raised its stake in Radius Health by 69.5% in the fourth quarter. Highbridge Capital Management LLC now owns 100,000 shares of the biopharmaceutical company’s stock worth $3,803,000 after buying an additional 41,000 shares during the last quarter. 97.66% of the stock is owned by institutional investors and hedge funds.
Shares of Radius Health, Inc. (NASDAQ RDUS) traded up 0.28% during midday trading on Friday, hitting $35.52. 539,938 shares of the company were exchanged. Radius Health, Inc. has a 52-week low of $31.58 and a 52-week high of $59.22. The company has a 50-day moving average price of $41.97 and a 200-day moving average price of $40.13. The stock’s market capitalization is $1.55 billion.
Radius Health (NASDAQ:RDUS) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.35) by $0.23. The business had revenue of $0.98 million during the quarter, compared to the consensus estimate of $1.96 million. During the same period last year, the business earned ($1.01) EPS. On average, analysts forecast that Radius Health, Inc. will post ($5.51) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.com-unik.info/2017/08/19/california-public-employees-retirement-system-has-2-71-million-position-in-radius-health-inc-nasdaqrdus-updated-updated-updated.html.
RDUS has been the subject of a number of research reports. Zacks Investment Research lowered shares of Radius Health from a “hold” rating to a “sell” rating in a report on Wednesday, April 26th. Cantor Fitzgerald reissued a “buy” rating and issued a $65.00 price objective on shares of Radius Health in a report on Friday, April 28th. Canaccord Genuity reissued a “buy” rating on shares of Radius Health in a report on Friday, April 28th. Maxim Group reissued a “sell” rating on shares of Radius Health in a report on Monday, May 1st. Finally, Cowen and Company lowered shares of Radius Health from an “outperform” rating to a “market perform” rating in a report on Tuesday, May 2nd. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company. Radius Health currently has an average rating of “Hold” and an average price target of $53.60.
In other Radius Health news, major shareholder Growth N. V. Biotech purchased 40,000 shares of the stock in a transaction on Tuesday, May 30th. The stock was bought at an average price of $34.21 per share, for a total transaction of $1,368,400.00. Following the acquisition, the insider now directly owns 5,038,799 shares of the company’s stock, valued at $172,377,313.79. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Growth N. V. Biotech purchased 150,000 shares of the stock in a transaction on Thursday, August 10th. The stock was acquired at an average price of $34.97 per share, with a total value of $5,245,500.00. Following the acquisition, the insider now directly owns 5,113,799 shares in the company, valued at $178,829,551.03. The disclosure for this purchase can be found here. Insiders acquired a total of 290,000 shares of company stock valued at $10,222,700 in the last 90 days. 15.00% of the stock is owned by company insiders.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
What are top analysts saying about Radius Health Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Radius Health Inc. and related companies.